Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 21;9(4):417-426.
doi: 10.1093/ehjqcco/qcac043.

Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry

Affiliations

Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry

Ofer Kobo et al. Eur Heart J Qual Care Clin Outcomes. .

Abstract

Background: Multisite artery disease is considered a 'malignant' type of atherosclerotic disease associated with an increased cardiovascular risk, but the impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention (PCI) is unknown.

Methods: Patients enrolled in the large, prospective e-Ultimaster study were grouped into (1) those without known prior vascular disease, (2) those with known single-territory vascular disease, and (3) those with known two to three territories (i.e coronary, cerebrovascular, or peripheral) vascular disease (multisite artery disease). The primary outcome was coronary target lesion failure (TLF), defined as the composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target lesion revascularization at 1-year. Inverse propensity score weighted (IPSW) analysis was performed to address differences in baseline patient and lesion characteristics.

Results: Of the 37 198 patients included in the study, 62.3% had no prior known vascular disease, 32.6% had single-territory vascular disease, and 5.1% had multisite artery disease. Patients with known vascular disease were older and were more likely to be men and to have more co-morbidities. After IPSW, the TLF rate incrementally increased with the number of diseased vascular beds (3.16%, 4.44%, and 6.42% for no, single, and multisite artery disease, respectively, P < 0.01 for all comparisons). This was also true for all-cause death (2.22%, 3.28%, and 5.29%, P < 0.01 for all comparisons) and cardiac mortality (1.26%, 1.91%, and 3.62%, P ≤ 0.01 for all comparisons).

Conclusions: Patients with previously known vascular disease experienced an increased risk of adverse cardiovascular events and mortality post-PCI. This risk is highest among patients with multisite artery disease.

Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02188355.

Keywords: Poly-vascular disease; clinical trial; human; percutaneous coronary intervention; vascular disease.

PubMed Disclaimer

Conflict of interest statement

Authors’ contributions

Drafting of the manuscript: O.K., M.S., and A.R.

Critical revision of the manuscript for important intellectual content: C.v.B., P.A.L.T., A.I.-R., O.F., M.H., R.M.O., J.P., A.J.J.I., A.A., M.R., and M.A.M.

Data availability

Data are available upon reasonable request from the study sponsor.

Figures

Graphical Abstract
Graphical Abstract
Number of diseased arterial beds is a prognostic factor for a cardiac event after a percutaneous coronary intervention.
Figure 1
Figure 1
Patient disposition.
Figure 2
Figure 2
Cumulative event curves after inverse-propensity score weighting. Target lesion failure (a); patient-oriented composite outcome (POCE) (b); cardiac death (c); target vessel myocardial infarction (d); clinically driven target lesion revascularization (CD-TLR) (e); definite/probable stent thrombosis (f).

References

    1. Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular disease: reappraisal of the current clinical landscape. Circ Cardiovasc Interv 2019;12:e007385. - PMC - PubMed
    1. Darmon A, Elbez Y, Bhatt DL, Abtan J, Mas JL, Cacoub Pet al. . Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. Ann Cardiol Angeiol (Paris) 2020;69:158–166. - PubMed
    1. Shi R, Babu S. Modern approaches and innovations in the diagnosis and treatment of peripheral vascular diseases. Front Biosci (Schol Ed) 2021;13:173–180. - PubMed
    1. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert Tet al. . 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO) the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. - PubMed
    1. Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KPet al. . Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes 2012;5:541–549. - PMC - PubMed

Publication types

Associated data